Monday, April 7, 2:35 - 4:05 p.m. - Room Van Dongen

Contribution of refluxate in the genesis of esophageal lesions

R. Fitzgerald  (UK)  -  H.S. Garewal (USA)
Discussant:  E. Montgomery (USA)

Introduction H.S. Garewal (Tucson)
Role of refluxate induced inflammatory mediators G.J.S. Jenkins (Swansea)

Dysregulation in cell/cycling apoptosis in GERD and Barrett's K. Dvorak (Tucson)
Free-radical production / DNA damage in response to acid and bile J. Räsänen (Helsinki)

What is the risk of developing Barrett’s esophagus in the post-esophagectomy esophageal remnant? S.J. Sontag (Chicago)

Summary R. Fitzgerald (Cambridge)

     


Monday, April 7, 5:00 - 6:30 p.m. - Room Van Dongen

Endoscopic approaches to Barrett's esophagus and dysplasia

P.D. Siersema (The Netherlands) – G. Triadafilopoulos (USA)
Discussant:  R. Dumas (Monaco)
What are the limits of 5-ALA in PDT for superficial adenocarcinoma?
P.D. Siersema (Utrecht)
- What is the rate of dysplasia healed without re-epithelialization?
What are the indications and complications of mucosal resection? K.K. Wang  (Rochester)
- What is the risk of metachronous lesions following mucosectomy?
- What factors should incite to avoid indication of mucosectomy?

What is the compared effect of balloon-occluded radiofrequency and EMR in patients with Barrett's esophagus? G. Triadafilopoulos  (Stanford) 
Is it possible to correlate the various means of endoscopic eradication of Barrett's esophagus with prevention of adenocarcinoma? H.C. Wolfsen (Jacksonville)
- Given the relatively low risk of cancer, do the potential benefits of the various endoscopic procedures exceed their risks?
What are the current indications for endo-luminal gastroplication? S. Kraemer (Redmond)

     
Tuesday, April 8, 2:35 - 4:05 p.m. - Room Van Dongen

Pre-operative staging of esophageal cancer

J. Salo (Finland)  -  M.Y. Ke (China)
Discussant:  D.H. Ilson (USA)
What is the accuracy of EUS T staging, when compared to surgical pathology following resection? Yang Ai Ming (Beijing)
What is the compared role of EUS and laparoscopy in N staging? G. Piessen (Lille)
What is the proportion of false negative / positive results in pre-operative evaluation of cancer by PET scan? D.H. Ilson (New York)
- Is PET scan more reliable than pre-operative CT scan-EUS?
Can use of new tracing molecules increase the accuracy of PET scan for pre-operative staging? G. O'Sullivan (Cork)
- Should staging laparoscopy be performed as a separate procedure?
Is PET scan a reliable means for evaluation of response to neo-adjuvant radio-chemotherapy? H.J. Stein  (Salzburg) 

What is the influence of the stage migration (Will Rogers phenomenon) on the expected survival of patients with early and advanced cancers? A. Chak  (Cleveland)

     


Tuesday, April 8, 5:00 - 6:30 p.m. - Room Van Dongen

Chemotherapy for esophageal adenocarcinoma

D.H. Ilson (USA) - J.M. Collard (Belgium)
Discussant:  F. Lordick (Germany)
What can be expected from gene bio-markers to individualize patients for primary or adjuvant chemotherapy? S.J. Meltzer (Baltimore)
- What is the value of pre-operative measurement of C-reactive protein?
Can the respective indications for chemotherapy vs chemo-radiation therapy be specified? M. Hurmuzlu (Bergen)
- What can be expected from the novel non CDDP and/or non 5FU regimens?
What can be expected from biomarkers for evaluation of potential response to chemotherapy and radiation? R. Langer (Munich)
Can microarray technology help in individualizing the optimal multi-modal treatment? J. Theisen (Munich)

Should incorporation of novel molecularly targeted agents directed towards receptors involved in cell proliferation be recommended? F. Lordick (Heidelberg)

Is exclusive chemotherapy a feasible option for loco-regionally advanced carcinomas in responders patients? T. Aikou (Kagoshima)

     


Wednesday, April 9, 2:35 - 4:05 p.m. - Room Van Dongen

Obesity and GERD

B.C. Jacobson (USA)  - L. Biertho (Canada)
Discussant: D. Nocca  (France)
What is the effect of early and late meals on GERD and obesity, and their relationship with BMI? R.K. Wong (Washington)
What is the best antireflux procedure for morbidly obese patients? J.Gugenheim (Nice)
Can the mechanisms by which abdominal obesity increase the risk of Barrett's esophagus and esophageal adenocarcinoma be defined? B.C. Jacobson(Boston)
What is the efficacy of the duodenal switch in obese patients? V.N. Prachand (Chicago)
What can be expected from gastroplasties performed through trans-oral route? S. Edmundowicz  (St Louis)

     


Wednesday, April 9, 5:00 - 6:30 p.m. - Room Van Dongen

Eosinophilic esophagitis

G. Furuta (USA)  -  A. Straumann (Switzerland)
Discussant:  F. Mal (France)
Immunopathogenesis of EE. H.U. Simon (Bern)

Pathological diagnosis, diagnostic criteria and genetics of EE. M.H. Collins (Cincinnati)

Clinical and endoscopical presentation of EE in children and dietary therapy  
G.T. Furuta (Denver)

Clinical and endoscopical presentation of EE in adults and medical therapy
A. Straumann (Olten)
Final question to the experts: All panelists